A Locke Lord team represented Zydus Pharmaceuticals (USA) Inc. at trial against Shire Development LLC in Shire’s effort to prevent Zydus from bringing to market a generic version of the drug LIALDA® (mesalamine). Judge Kent Jordan, a Third Circuit appellate judge sitting by designation in the United States District Court for the District of Delaware, ruled that Zydus’s proposed generic product would not infringe Shire’s patent. LIALDA® is the first and only FDA-approved once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission of ulcerative colitis. LIALDA® is also the number one prescribed mesalamine product in the United States. Shire has reported annual global sales of approximately $700 million for this product (which is sold under the name MEZAVANT outside the United States). The Locke Lord team representing Zydus included: Michael J. Gaertner, Keith D. Parr, James T. Peterka, David B. Abramowitz, Andy J. Miller, Wasim K. Bleibel and Timothy F. Peterson (all Chicago).
Posted October 5, 2016